Gapping down
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- PFE -1.4% (amends U.S. Government Paxlovid agreement; lowers FY23 revenue and earnings guidance solely due to COVID products)
Other news:
- BNTX -6.7% (provides update regarding Pfizer's (PFE) statement on COMIRNATY-related write-offs)
- VSTM -5.2% (Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS (sotorasib) in KRAS G12C-Mutant Non-Small Cell Lung Cancer) MRNA -4.4% (in sympathy with PFE)
- NVAX -3.5% (EU expected to delay approval of NVAX COVIVD-19 vaccine according to FT; also in sympathy with PFE)
- NUVL -3.5% (commences offering of $300.0 mln of its shares of Class A common stock)
- BDTX -2.2% (Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535)
- IRWD -2% (presents positive final data from STARS nutrition a phase II study of apraglutide in short bowel syndrome with intestinal failure and colon in continuity at United European Gastroenterology Week)
- HSIC -1.8% (provides information on cybersecurity incident)
Analyst comments:
- ENPH -2.4% (downgraded to Market Perform from Outperform at BMO Capital Markets)
- BCC -2.3% (downgraded to Underperform from Neutral at BofA Securities)
- WHD -2% (downgraded to Underperform from Neutral at BofA Securities)
- MPW -1.6% (downgraded to Underweight from Equal Weight at Wells Fargo)
- CCI -0.8% (downgraded to Sector Perform from Outperform at RBC Capital Mkts)